Skip to content
Screener

Arbutus Biopharma Corporation ABUS Unrealized Losses on Investments (Before Tax)

Unrealized Losses on Investments (Before Tax) at other companies

Gilead Sciences logo
Gilead SciencesGILD
$1M—
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$1.71M+3,119%
Prime Medicine logo
Prime MedicinePRME
$9K-10.0%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$4.01M+103%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$227K+1,035%

Other financials

Income statement

See full
Revenue$179.1M+10,055%
Operating income$168.9M+757%
Net income$169.7M+792%
EPS (diluted)$0.87+769%

Balance sheet

See full
Cash & equivalents$23.7M-36.1%
Total debt$631.0K-46.9%
Total equity$260.2M+229%
Total assets$277.2M+137%

Cash flow

See full
Operating cash flow-$8.1M+39.4%
CapEx--100%
Free cash flow-$4.7M+55.0%

Valuation

See full
Market cap$906.7M+41.2%
Enterprise value$883.62M+45.8%
P/E5.6×—
P/S4.7×-37.0×

Profitability

See full
Operating margin81.7%+42.1pp
Net margin84%+43.4pp
FCF margin-281.5%-119pp

Returns & leverage

See full
Return on equity94.7%+65.1pp
Debt / equity0×0.0×
Current ratio54.3×+48.3×

Where this comes from

Reported directly by Arbutus Biopharma Corporation in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.

The source filing: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 7:31 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001447028-26-000021
As of March 31, 2026Amortized Cost / (in thousands)Gross Unrealized Gain(1) / (in thousands)Gross Unrealized Loss(1) / (in thousands)Fair Value / (in thousands)
Cash equivalents
Money market funds$14,487——$14,487
Total$14,487——$14,487
Investments in marketable short-term securities
US treasury bills33,5515(11)33,545
US government bonds37,9798(12)37,975
Total$71,530$13$(23)$71,520

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

FAQ

What is Arbutus Biopharma Corporation's unrealized losses on investments (before tax)?
Arbutus Biopharma Corporation (ABUS) reported unrealized losses on investments (before tax) of $23K in Q1 2026.
How has Arbutus Biopharma Corporation's unrealized losses on investments (before tax) changed year-over-year?
Arbutus Biopharma Corporation's unrealized losses on investments (before tax) increased by 360.0% year-over-year, from $5K to $23K.
What is the long-term trend for Arbutus Biopharma Corporation's unrealized losses on investments (before tax)?
Over 2 years (2020 to 2025), Arbutus Biopharma Corporation's unrealized losses on investments (before tax) has grown at a -100.0% compound annual growth rate (CAGR), from $1K to $0.

Ask your AI about Arbutus Biopharma Corporation's unrealized losses on investments (before tax).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude